{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:29:47Z","timestamp":1794047387140,"version":"4.8.0"},"reference-count":46,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"5","license":[{"start":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T00:00:00Z","timestamp":1626912000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) may manifest as thrombosis, stroke, renal failure, myocardial infarction, and thrombocytopenia, reminiscent of other complement- mediated diseases. Multiple clinical and preclinical studies have implicated complement in the pathogenesis of COVID-19 illness. We previously found that the SARS-CoV-2 spike protein activates the alternative pathway of complement (APC) in vitro through interfering with the function of complement factor H, a key negative regulator of APC. Here, we demonstrated that serum from 58 COVID-19 patients (32 patients with minimal oxygen requirement, 7 on high flow oxygen, 17 requiring mechanical ventilation and 2 deaths) can induce complementmediated cell death in a functional assay (the modified Ham test) and increase membrane attack complex (C5b-9) deposition on the cell surface. A positive modified Ham assay (&gt;20% cell-killing) was present in 41.2% COVID-19 patients requiring intubation (n=7\/17) and only 6.3% in COVID-19 patients requiring minimal oxygen support (n=2\/32). C5 and factor D inhibition effectively mitigated the complement amplification induced by COVID-19 patient serum. Increased serum factor Bb level was associated with disease severity in COVID-19 patients, suggesting that APC dysregulation plays an important role. Moreover, SARS-CoV-2 spike proteins directly block complement factor H from binding to heparin, which may lead to complement dysregulation on the cell surface. Taken together, our data suggest that complement dysregulation contributes to the pathogenesis of COVID-19 and may be a marker of disease severity.<\/jats:p>","DOI":"10.3324\/haematol.2021.279155","type":"journal-article","created":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T05:49:43Z","timestamp":1626932983000},"page":"1095-1105","source":"Crossref","is-referenced-by-count":57,"title":["Complement dysregulation is associated with severe COVID-19 illness"],"prefix":"10.3324","volume":"107","author":[{"given":"Jia","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria F.","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Chaturvedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan M.","family":"Braunstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Brodsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2021,7,22]]},"reference":[{"key":"35477","doi-asserted-by":"crossref","unstructured":"Java A, Apicelli AJ, Liszewski MK. The complement system in COVID-19: friend and foe?. JCI Insight. 2020; 5(15):e140711.","DOI":"10.1172\/jci.insight.140711"},{"key":"35478","doi-asserted-by":"crossref","unstructured":"Gavriilaki E, Brodsky RA. Severe COVID- 19 infection and thrombotic microangiopathy: success does not come easily. Br J Haematol. 2020; 189(6):e227-e230.","DOI":"10.1111\/bjh.16783"},{"key":"35479","doi-asserted-by":"crossref","unstructured":"Risitano AM, Mastellos DC, Huber-Lang M. Complement as a target in COVID-19?. Nat Rev Immunol. 2020; 20(6):343-344.","DOI":"10.1038\/s41577-020-0320-7"},{"key":"35480","doi-asserted-by":"crossref","unstructured":"Campbell CM, Kahwash R. Will complement inhibition be the new target in treating COVID-19-related systemic thrombosis?. Circulation. 2020; 141(22):1739-1741.","DOI":"10.1161\/CIRCULATIONAHA.120.047419"},{"key":"35481","doi-asserted-by":"crossref","unstructured":"Chaturvedi S, Braunstein EM, Yuan X. Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. Blood. 2020; 135(4):239-251.","DOI":"10.1182\/blood.2019003863"},{"key":"35482","doi-asserted-by":"crossref","unstructured":"Baines AC, Brodsky RA. Complementopathies. Blood Rev. 2017; 31(4):213-223.","DOI":"10.1016\/j.blre.2017.02.003"},{"key":"35483","doi-asserted-by":"crossref","unstructured":"Wichmann D, Sperhake JP, L\u00fctgehetmann M. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med. 2020; 173(4):268-277.","DOI":"10.7326\/M20-2003"},{"key":"35484","doi-asserted-by":"crossref","unstructured":"Diao B, Wang C, Wang R. Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection. Nat Commun. 2021; 12(1):1-9.","DOI":"10.1038\/s41467-021-22781-1"},{"key":"35485","doi-asserted-by":"crossref","unstructured":"Carvelli J, Demaria O, V\u00e9ly F. Association of COVID-19 inflammation with activation of the C5a\u2013C5aR1 axis. Nature. 2020; 588(7836):146-150.","DOI":"10.1136\/jitc-2020-SITC2020.0483"},{"key":"35486","doi-asserted-by":"crossref","unstructured":"Cugno M, Meroni PL, Gualtierotti R. Complement activation in patients with COVID-19: a novel therapeutic target. J Allergy Clin Immunol. 2020; 146(1):215-217.","DOI":"10.1016\/j.jaci.2020.05.006"},{"key":"35487","doi-asserted-by":"crossref","unstructured":"de Nooijer AH, Grondman I, Janssen NAF. Complement activation in the disease course of coronavirus disease 2019 and its effects on clinical outcomes. J Infect Dis. 2021; 223(2):214-224.","DOI":"10.1093\/infdis\/jiaa646"},{"key":"35488","unstructured":"Diurno F, Numis FG, Porta G. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci. 2020; 24(7):4040-4047."},{"key":"35489","doi-asserted-by":"crossref","unstructured":"Annane D, Heming N, Grimaldi-Bensouda L. Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study. EClinicalMedicine. 2020; 28:100590.","DOI":"10.1016\/j.eclinm.2020.100590"},{"key":"35490","doi-asserted-by":"crossref","unstructured":"Mastaglio S, Ruggeri A, Risitano AM. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol. 2020; 215:108450.","DOI":"10.1016\/j.clim.2020.108450"},{"key":"35491","doi-asserted-by":"crossref","unstructured":"Ling M, Murali M. Analysis of the complement system in the clinical immunology laboratory. Clin Lab Med. 2019; 39(4):579-590.","DOI":"10.1016\/j.cll.2019.07.006"},{"key":"35492","doi-asserted-by":"crossref","unstructured":"Kourtzelis I, Markiewski MM, Doumas M. Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis. Blood. 2010; 116(4):631-639.","DOI":"10.1182\/blood-2010-01-264051"},{"key":"35493","doi-asserted-by":"crossref","unstructured":"Yu J, Yuan X, Chen H, Chaturvedi S, Braunstein EM, Brodsky RA. Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D Inhibition. Blood. 2020; 136(18):2080-2089.","DOI":"10.1182\/blood.2020008248"},{"key":"35494","doi-asserted-by":"crossref","unstructured":"Gavriilaki E, Yuan X, Ye Z. Modified Ham test for atypical hemolytic uremic syndrome. Blood. 2015; 125(23):3637-3646.","DOI":"10.1182\/blood-2015-02-629683"},{"key":"35495","doi-asserted-by":"crossref","unstructured":"Vaught AJ, Braunstein EM, Jasem J. Germline mutations in the alternative pathway of complement predispose to HELLP syndrome. JCI Insight. 2018; 3(6):5-7.","DOI":"10.1172\/jci.insight.99128"},{"key":"35496","unstructured":"World Health Organization. COVID-19 Therapeutic Trial Synopsis. World Health Organization. 2020. Publisher Full Text|"},{"key":"35497","doi-asserted-by":"crossref","unstructured":"Yuan X, Yu J, Gerber G. Ex vivo assays to detect complement activation in complementopathies. Clin Immunol. 2020; 221:108616.","DOI":"10.1016\/j.clim.2020.108616"},{"key":"35498","doi-asserted-by":"crossref","unstructured":"Vaught AJ, Braunstein EM, Jasem J. Germline mutations in the alternative pathway of complement predispose to HELLP syndrome. JCI Insight. 2018; 3(6):e99128.","DOI":"10.1172\/jci.insight.99128"},{"key":"35499","doi-asserted-by":"crossref","unstructured":"Clausen TM, Sandoval DR, Spliid CB. SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2. Cell. 2020; 183(4):1043-1057.e15.","DOI":"10.1016\/j.cell.2020.09.033"},{"key":"35500","doi-asserted-by":"crossref","unstructured":"Magro C, Mulvey JJ, Berlin D. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 2020; 220:1-13.","DOI":"10.1016\/j.trsl.2020.04.007"},{"key":"35501","doi-asserted-by":"crossref","unstructured":"Holter JC, Pischke SE, de Boer E. Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients. Proc Natl Acad Sci U S A. 2020; 117(40):25018-25025.","DOI":"10.1073\/pnas.2010540117"},{"key":"35502","doi-asserted-by":"crossref","unstructured":"Sinkovits G, Mez\u0151 B, R\u00e9ti M. Complement overactivation and consumption predicts in-hospital mortality in SARSCoV- 2 infection. Front Immunol. 2021; 12:663187.","DOI":"10.3389\/fimmu.2021.663187"},{"key":"35503","doi-asserted-by":"crossref","unstructured":"Ramlall V, Thangaraj PM, Meydan C. Immune complement and coagulation dysfunction in adverse outcomes of SARSCoV- 2 infection. Nat Med. 2020; 26(10):1609-1615.","DOI":"10.1038\/s41591-020-1021-2"},{"key":"35504","doi-asserted-by":"crossref","unstructured":"Valenti L, Griffini S, Lamorte G. Chromosome 3 cluster rs11385942 variant links complement activation with severe COVID-19. J Autoimmun. 2021; 117:102595.","DOI":"10.1016\/j.jaut.2021.102595"},{"key":"35505","doi-asserted-by":"crossref","unstructured":"Gavriilaki E, Asteris PG, Touloumenidou T. Genetic justification of severe COVID-19 using a rigorous algorithm. Clin Immunol. 2021; 226:108726.","DOI":"10.1016\/j.clim.2021.108726"},{"key":"35506","doi-asserted-by":"crossref","unstructured":"Jang S, Rhee JY, Wi YM, Jung BK. Viral kinetics of SARS-CoV-2 over the preclinical, clinical, and postclinical period. Int J Infect Dis. 2021; 102:561-565.","DOI":"10.1016\/j.ijid.2020.10.099"},{"key":"35507","doi-asserted-by":"crossref","unstructured":"Sun J, Tang X, Bai R. The kinetics of viral load and antibodies to SARS-CoV-2. Clin Microbiol Infect. 2020; 26(12):1690.e1-1690.e4.","DOI":"10.1016\/j.cmi.2020.08.043"},{"key":"35508","doi-asserted-by":"crossref","unstructured":"Messner CB, Demichev V, Wendisch D. Ultra-high-throughput clinical proteomics reveals classifiers of COVID-19 infection. Cell Syst. 2020; 11(1):11-24.","DOI":"10.1016\/j.cels.2020.05.012"},{"key":"35509","doi-asserted-by":"crossref","unstructured":"Yan B, Freiwald T, Chauss D. SARSCoV- 2 drives JAK1\/2-dependent local complement hyperactivation. Sci Immunol. 2021; 6(58):1-20.","DOI":"10.1126\/sciimmunol.abg0833"},{"key":"35510","doi-asserted-by":"crossref","unstructured":"Macor P, Durigutto P, Mangogna A. Multi-organ complement deposition in COVID-19 patients. medRxiv. 2021.","DOI":"10.1101\/2021.01.07.21249116"},{"key":"35511","unstructured":"Pekayvaz K, Leunig A, Kaiser R. Protective immune trajectories in early viral containment of non-pneumonic SARSCoV- 2 infection. bioRxiv.Publisher Full Text|"},{"key":"35512","doi-asserted-by":"crossref","unstructured":"Ma L, Sahu SK, Cano M. Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection. Sci Immunol. 2021; 6(59):1-18.","DOI":"10.1126\/sciimmunol.abh2259"},{"key":"35513","doi-asserted-by":"crossref","unstructured":"Mastellos DC, Pires da Silva BGP, Fonseca BAL. Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy. Clin Immunol. 2020; 220:108598.","DOI":"10.1016\/j.clim.2020.108598"},{"key":"35514","doi-asserted-by":"crossref","unstructured":"Rambaldi A, Gritti G, Mic\u00f2 MC. Endothelial injury and thrombotic microangiopathy in COVID-19: treatment with the lectin-pathway inhibitor narsoplimab. Immunobiology. 2020; 225(6):152001.","DOI":"10.1016\/j.imbio.2020.152001"},{"key":"35515","doi-asserted-by":"crossref","unstructured":"Perkins SJ, Fung KW, Khan S. Molecular interactions between complement factor H and its heparin and heparan sulfate ligands. Front Immunol. 2014; 5:1-14.","DOI":"10.3389\/fimmu.2014.00126"},{"key":"35516","doi-asserted-by":"crossref","unstructured":"Polack FP, Thomas SJ, Kitchin N. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383(27):2603-2615.","DOI":"10.1056\/NEJMoa2034577"},{"key":"35517","doi-asserted-by":"crossref","unstructured":"Baden LR, El Sahly HM, Essink B. Efficacy and safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021; 384(5):403-416.","DOI":"10.1056\/NEJMoa2035389"},{"key":"35518","doi-asserted-by":"crossref","unstructured":"Gavriilaki E, Brodsky RA. Complementopathies and precision medicine. J Clin Invest. 2020; 130(5):2152-2163.","DOI":"10.1172\/JCI136094"},{"key":"35519","doi-asserted-by":"crossref","unstructured":"Ville S, Le Bot S, Chapelet-Debout A. Atypical HUS relapse triggered by COVID- 19. Kidney Int. 2021; 99(1):267-268.","DOI":"10.1016\/j.kint.2020.10.030"},{"key":"35520","doi-asserted-by":"crossref","unstructured":"Gerber GF, Yuan X, Yu J. COVID-19 Vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria. Blood. 2021; 137(26):3670-3673.","DOI":"10.1182\/blood.2021011548"},{"key":"35521","doi-asserted-by":"crossref","unstructured":"Shim K, Begum R, Yang C, Wang H. Complement activation in obesity, insulin resistance, and type 2 diabetes mellitus. World J Diabetes. 2020; 11(1):1-12.","DOI":"10.4239\/wjd.v11.i1.1"},{"key":"35522","doi-asserted-by":"crossref","unstructured":"Kulkarni S, Fisk M, Kostapanos M. Repurposed immunomodulatory drugs for Covid-19 in pre-ICU patients - multi-arm Therapeutic study in pre-ICU patients admitted with Covid-19 - repurposed drugs (TACTIC-R): a structured summary of a study protocol for a randomised controlled trial. Trials. 2020; 21(1):20-22.","DOI":"10.1186\/s13063-020-04535-4"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.279155\/73527","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.279155\/74395","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10339\/73527","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:00:00Z","timestamp":1794045600000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2021.279155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,22]]},"references-count":46,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2021.279155","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7,22]]}}}